Coreline Soft to showcase advanced AI solutions at SCCT 2024 in Washington DC

Coreline Soft said on Tuesday that it would attend the annual meeting of the Society of Cardiovascular Computed Tomography (SCCT 2024) in Washington DC, the U.S. from July 18-21. SCCT is a cardiovascular CT expert society with members from more than 85 countries around the world. The upcoming event is designed to promote research, education, and clinical excellence in cardiology.

Coreline Soft will install an exclusive booth at SCCT 2024 to demonstrate its lineup of emergency disease solutions, including AVIEW CAC, an AI cardiovascular diagnostic solution. AVIEW CAC uses deep learning-based AI trained on large amounts of cardiac data to locate coronary arteries, automatically classify and quantify coronary calcification in the four main coronary arteries, and provide a risk of coronary artery disease based on the Multi-Ethnic Study of Atherosclerosis (MESA) study. Specifically, it quantitatively assesses CAC in chest CT scans to streamline the diagnostic process and improve diagnostic effectiveness, and has received U.S. FDA 510(k) clearance.

During the event, Coreline Soft will also be demonstrating AVIEW Aorta, a cardiovascular image detection and diagnosis assistant software. This AI-powered solution quickly and accurately diagnoses aortic dissection, which has a high fatality rate. It has been awarded the 3rd class of innovative medical device in Korea.

In addition, the company will introduce a lineup of emergency diagnostic solutions, including AVIEW PE, a pulmonary embolism diagnostic aid designated as an innovative medical device last month, and AVIEW HeartX, a deep learning-based chest X-ray cardiovascular disease diagnostic solution.

At the event, Coreline Soft will also release four studies utilizing AVIEW CAC. The studies will demonstrate high reliability in reading CAC scores compared to human experts; efficiency, with AI integration significantly improving reading time and accuracy; broad applicability, with consistent performance across different demographics and different imaging methods; and innovation, with the ability to effectively read CAC scores using non-gated CT images without additional radiation exposure, the company said.

The studies will be presented in two papers by Sina Kianoush, MDm MPH, and Jairo Aldana-bitar, MD, from The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.